Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Orexo ABORXOY -14.29%37 Cash Ratio is 1.20 as of Jun. 2026, which is 14% above its 10-year median of 1.05. GuruFocus rates ORXOY with a GF Score™ of 37/100 and a GF Value™ of $0.31 (Significantly Overvalued). The stock has 7 warning signs investors should review. Among 974 Drug Manufacturers companies, Orexo AB ranks better than 66.53% on this metric.
Orexo AB has a Cash Ratio of 1.20. It generally indicates that the company is able to cover all short-term debt and still have cash remaining.
The historical rank and industry rank for Orexo AB's Cash Ratio or its related term are showing as below:
ORXOY'
s Cash Ratio Range Over the Past 10 Years
Min: 0.26 Med: 1.05 Max: 2.9
Current: 1.2
During the past 13 years, Orexo AB's highest Cash Ratio was 2.90. The lowest was 0.26. And the median was 1.05.
ORXOY's Cash Ratio is ranked better than 66.53% of 974
companies
in the Drug Manufacturers industry
Industry Median: 0.61
vs ORXOY: 1.20
Orexo AB (OTCPK:ORXOY) Cash Ratio Explanation
The cash ratio is more conservative than other liquidity ratios, such as Quick Ratio and Current Ratio, because it only considers a company's most liquid resources. The numerator of cash ratio only considers Cash, Cash Equivalents and marketable securities. Other current assets, such as accounts receivable and inventories, are not included. The rationale is that these assets may require time to be transformed into cash, and the amount of money received is also uncertain.
The cash ratio shows a company’s ability to pay all current liabilities immediately without selling or liquidating other assets. Generally speaking, a higher cash ratio suggests the company has a stronger ability to cover its short-term debt. However, a high cash ratio could also indicate inefficient management: the company is inefficient in making full utilization of cash to invest protential profitable project. It may also suggest that the company is not confident about future profitability.
In general, the higher the cash ratio, the better the company's liquidity position.
Orexo AB Cash Ratio Related Terms
Orexo AB Cash Ratio Historical Data
* Premium members only.
The historical data trend for Orexo AB's Cash Ratio can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - Specialty & Generic subindustry, Orexo AB's Cash Ratio, along with its competitors' market caps and Cash Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Orexo AB Cash Ratio vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Orexo AB's Cash Ratio distribution charts can be found below:
* The bar in red indicates where Orexo AB's Cash Ratio falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Orexo AB (ORXOY) has a Cash Ratio of 1.20 as of Jun. 2026. Cashflow ratio is the ratio of Cash, Cash Equivalents, Marketable Securities to current liabilities. View historical data on Orexo AB and its competitors. This is 14% above median its historical median of 1.05. Over the past decade, Orexo AB's Cash Ratio has ranged from 0.26 to 2.90. According to the industry distribution chart, Orexo AB ranks #326 out of 974 companies in the Drug Manufacturers industry, placing it in the top 33.5%.
Is Orexo AB's Cash Ratio too high?
Orexo AB's current Cash Ratio of 1.20 is 14% above median its 10-year median of 1.05. Over the past 10 years, this metric has ranged from a low of 0.26 to a high of 2.90. The Drug Manufacturers industry median Cash Ratio is 0.61. Orexo AB's value of 1.20 is 96.7% above this industry median. Based on the distribution chart, Orexo AB ranks #326 out of 974 companies in the Drug Manufacturers industry, which is above the industry midpoint. Overall, Orexo AB has a GF Score™ of 37/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Orexo AB's Cash Ratio compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, Orexo AB ranks #326 out of 974 companies for Cash Ratio. This puts Orexo AB in the upper half of its industry. The industry median Cash Ratio is 0.61. Orexo AB's value of 1.20 is 96.7% above this benchmark. Historically, Orexo AB's own Cash Ratio has ranged from 0.26 to 2.90 over the past decade. While the company's 10-year median is 1.05 vs. the industry median of 0.61, Orexo AB has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Cash Ratio for a Drug Manufacturers company?
The median Cash Ratio among Drug Manufacturers companies is 0.61, based on 974 companies in the industry. Companies in the top quartile (top 25%) have a Cash Ratio significantly above this median, while those in the bottom quartile fall well below. However, Cash Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Orexo AB's current Cash Ratio of 1.20 is 96.7% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Cash Ratio mean?
A high Cash Ratio can signal that a stock is expensive relative to its fundamentals. Cashflow ratio is the ratio of Cash, Cash Equivalents, Marketable Securities to current liabilities. View historical data on Orexo AB and its competitors. For the Drug Manufacturers industry, the median Cash Ratio is 0.61 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Orexo AB's current Cash Ratio is 1.20, which is 14% above median its own 10-year median of 1.05. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Orexo AB stock overvalued right now?
Based on GuruFocus' analysis, Orexo AB (ORXOY) is currently considered Significantly Overvalued. The stock's GF Value™ is $0.31, compared to a current price of $1.80 — trading 480.6% above its estimated fair value. The current Cash Ratio is 1.20, which is 14% above median its 10-year median of 1.05 and 96.7% above the Drug Manufacturers industry median of 0.61. Orexo AB's overall GF Score™ is 37/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Cash Ratio calculated?
Cash Ratio is calculated from a company's financial statements. For Orexo AB (ORXOY), the current Cash Ratio is 1.20 as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Orexo AB (ORXOY) Overvalued in 2026?
Based on GuruFocus' analysis, Orexo AB stock appears to be overvalued.
The current stock price of $1.80 is trading 480.6% above its estimated GF Value™ of $0.31.
GuruFocus considers Orexo AB to be Significantly Overvalued.
Key valuation signals for ORXOY:
Cash Ratio: 1.20 (14% above median its 10-year median of 1.05)
GF Value™: $0.31 vs. price of $1.80 (480.6% above fair value)
Industry Position: 96.7% above the Drug Manufacturers median (#326 of 974)
No single metric tells the full story. See the ORXOY stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Orexo AB is a Swedish pharmaceutical company dedicated to advancing treatments for severe diseases and life-saving rescue medications to meet future healthcare needs, developing improved medications based on proprietary drug delivery technologies. At the core of its innovation is AmorphOX, which improves bioavailability and stability for both large and small molecules. It has developed four drugs from concept to approval, including Zubsolv, Abstral, Edluar, and Diabact UBT. The company's current development efforts focus on AmorphOX, with projects in preclinical and clinical phases across multiple therapeutic areas. It operates through US Commercial and HQ & Pipeline, which generate maximum revenue, and operates in the US, EU, and UK generating maximum revenue, and the Rest of the World.
37GF Score
Get the complete analysis for ORXOY
Cash Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ORXOY has been successfully added to your 
